An increased expression of pyruvate kinase M2 (PKM2), involved in glycolysis, serves as a biomarker for oxaliplatin resistance in colorectal and ovarian cancers, and the inhibition of PKM2 reverses this resistance [90,91,92]. This evidence concerns the gene PKM and ovarian cancer.